{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:18:20Z","timestamp":1773299900065,"version":"3.50.1"},"reference-count":255,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jtho.2017.05.019","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T03:18:54Z","timestamp":1496373534000},"page":"1183-1209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Scientific Advances in Thoracic Oncology 2016"],"prefix":"10.1016","volume":"12","author":[{"given":"Ross A.","family":"Soo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily C.A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Michael","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Jett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry J.M.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Mulshine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Bubendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Rami-Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank C.","family":"Detterbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Asamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Donington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lecia V.","family":"Sequist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel B.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leora","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Gettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murry W.","family":"Wynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2017.05.019_bib1","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2017-014","article-title":"Global cost of smoking passes $1 trillion","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2017.05.019_bib2","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.amepre.2016.10.036","article-title":"Overview of electronic nicotine delivery systems: a systematic review","volume":"52","author":"Glasser","year":"2017","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/tobaccocontrol-2016-053179","article-title":"Global approaches to regulating electronic cigarettes","volume":"26","author":"Kennedy","year":"2017","journal-title":"Tob Control"},{"key":"10.1016\/j.jtho.2017.05.019_bib4","series-title":"E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General","year":"2016"},{"key":"10.1016\/j.jtho.2017.05.019_bib5","unstructured":"McNeill A, Brose L, Calder R, et\u00a0al. E-cigarettes: an evidence update; a report commissioned by Public Health England. London, UK: 2015. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/457102\/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf. Accessed February 13,\u00a02017."},{"key":"10.1016\/j.jtho.2017.05.019_bib6","first-page":"CD010216","article-title":"Electronic cigarettes for smoking cessation","volume":"9","author":"Hartmann-Boyce","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2017.05.019_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S2213-2600(15)00521-4","article-title":"E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis","volume":"4","author":"Kalkhoran","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/JTO.0000000000000129","article-title":"E-cigarettes and cancer patients","volume":"9","author":"Cummings","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jtho.2017.05.019_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6511a1","article-title":"National estimates of marijuana use and related indicators\u2014National Survey on Drug Use and Health, United States, 2002-2014","volume":"65","author":"Azofeifa","year":"2016","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.jtho.2017.05.019_bib10","series-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","year":"2017"},{"key":"10.1016\/j.jtho.2017.05.019_bib11","first-page":"879","article-title":"Adverse health effects of marijuana use","volume":"371","author":"Volkow","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2017.05.019_bib13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1001\/jama.2015.6199","article-title":"Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review","volume":"313","author":"Hill","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2017.05.019_bib14","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.2016.68.5206","article-title":"Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Paice","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.0155","article-title":"Medical marijuana use in oncology: a review","author":"Wilkie","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2015.1858","article-title":"Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013","volume":"72","author":"Hasin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jtho.2017.05.019_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1513\/AnnalsATS.201407-333OC","article-title":"The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study","volume":"12","author":"Kempker","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtho.2017.05.019_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1513\/AnnalsATS.201212-127FR","article-title":"Effects of marijuana smoking on the lung","volume":"10","author":"Tashkin","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtho.2017.05.019_bib19","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1513\/AnnalsATS.201504-195AR","article-title":"Implications of marijuana decriminalization on the practice of pulmonary, critical care, and sleep medicine. a report of the American Thoracic Society Marijuana Workgroup","volume":"12","author":"Douglas","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtho.2017.05.019_bib20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ijc.29036","article-title":"Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium","volume":"136","author":"Zhang","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1055-9965.EPI-14-1026","article-title":"An epidemiologic review of marijuana and cancer: an update","volume":"24","author":"Huang","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2017.05.019_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20400","article-title":"The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer","volume":"20","author":"Field","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jtho.2017.05.019_bib23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1183\/09031936.00197712","article-title":"Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial","volume":"42","author":"Horeweg","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2017.05.019_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2016-208655","article-title":"Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval","volume":"72","author":"Yousaf-Khan","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2017.05.019_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7326\/0003-4819-158-4-201302190-00004","article-title":"Definition of a positive test result in computed tomography screening for lung cancer: a cohort study","volume":"158","author":"Henschke","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/M14-2086","article-title":"Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment","volume":"162","author":"Pinsky","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtho.2016.12.010","article-title":"Size and growth assessment of pulmonary nodules: consequences of the rounding","volume":"12","author":"Li","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S1470-2045(14)70387-0","article-title":"Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers","volume":"15","author":"Horeweg","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib29","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(14)70389-4","article-title":"Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening","volume":"15","author":"Horeweg","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1470-2045(16)30069-9","article-title":"Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial","volume":"17","author":"Walter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.21037\/atm.2016.04.11","article-title":"Advancing and sharing the knowledge base of CT screening for lung cancer","volume":"4","author":"Yankelevitz","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CEJ.0000000000000065","article-title":"The impact of the regimen of screening on lung cancer cure: a comparison of I-ELCAP and NLST","volume":"24","author":"Yip","year":"2015","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.jtho.2017.05.019_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2015.11.003","article-title":"CT screening for lung cancer: is the evidence strong enough?","volume":"91","author":"Field","year":"2016","journal-title":"Lung Cancer"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2017.05.019_bib34","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2015-207168","article-title":"British Thoracic Society guidelines for the investigation and management of pulmonary nodules","volume":"70","author":"Callister","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2017.05.019_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1055-9965.EPI-14-0745","article-title":"Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials","volume":"24","author":"Ten Haaf","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2017.05.019_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ntr\/ntv177","article-title":"Readiness of lung cancer screening sites to deliver smoking cessation treatment: current practices, organizational priority, and perceived barriers","volume":"18","author":"Ostroff","year":"2016","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14694\/EDBK_158704","article-title":"Lung cancer screening, cancer treatment, and addressing the continuum of health risks caused by tobacco","volume":"35","author":"Warren","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2017.05.019_bib38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2015.2472","article-title":"Cost-effectiveness of lung cancer screening in Canada","volume":"1","author":"Goffin","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.09.013","article-title":"Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness","volume":"101","author":"Goffin","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s12325-016-0319-4","article-title":"Navigational bronchoscopy for early lung cancer: a road to therapy","volume":"33","author":"Khan","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtho.2017.05.019_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.chest.2016.04.008","article-title":"Could cryo-biopsies lead bronchoscopy into the Ice Age?","volume":"150","author":"Pastis","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2017.05.019_bib42","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2016-0091-SA","article-title":"Biomarker testing in lung carcinoma cytology specimens: a perspective from members of the Pulmonary Pathology Society","author":"Roy-Chowdhuri","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib43","unstructured":"International Association for the Study of Lung Cancer. CAP\/IASLC\/AMP molecular testing guideline: open comment period. https:\/\/www.iaslc.org\/articles\/capiaslcamp-molecular-testing-guideline-open-comment-period. Accessed February 7,\u00a02017."},{"key":"10.1016\/j.jtho.2017.05.019_bib44","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/srep06269","article-title":"Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis","volume":"4","author":"Luo","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2017.05.019_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1055-9965.EPI-14-0895","article-title":"Circulating tumor DNA is\u00a0effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis","volume":"24","author":"Qiu","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2017.05.019_bib46","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1097\/MD.0000000000000775","article-title":"Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis","volume":"94","author":"Mao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtho.2017.05.019_bib47","doi-asserted-by":"crossref","first-page":"29154","DOI":"10.18632\/oncotarget.8684","article-title":"Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in\u00a0non-small cell lung cancer","volume":"7","author":"Qian","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2017.05.019_bib48","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","article-title":"ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS Study","volume":"11","author":"Reck","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib49","doi-asserted-by":"crossref","first-page":"66595","DOI":"10.18632\/oncotarget.10704","article-title":"Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma","volume":"7","author":"Rachiglio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2017.05.019_bib50","unstructured":"US Food and Drug Administration. FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm504488.htm. Accessed February 7\u00a02017."},{"key":"10.1016\/j.jtho.2017.05.019_bib51","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib52","doi-asserted-by":"crossref","unstructured":"Lisberg A, Garon EB. The value of PD-L1 testing in non-small-cell lung cancer [e-pub ahead of print]. JAMA Oncol. http:\/\/dx.doi.org\/10.1001\/jamaoncol.2016.0043, accessed March 21, 2017.","DOI":"10.1001\/jamaoncol.2016.0043"},{"key":"10.1016\/j.jtho.2017.05.019_bib53","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jtho.2016.02.015","article-title":"Predictive markers for the efficacy of anti-PD-1\/PD-L1 antibodies in lung cancer","volume":"11","author":"Shukuya","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/JTO.0000000000000526","article-title":"Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?","volume":"10","author":"Kerr","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5858\/arpa.2015-0506-SA","article-title":"Programmed death ligand-1 immunohistochemistry\u2014a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society","volume":"140","author":"Sholl","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed death ligand-1 immunohistochemistry: friend or foe?","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib58","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2017.05.019_bib59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2016.3015","article-title":"A\u00a0quantitative comparison of antibodies to programmed cell death 1 ligand 1","volume":"3","author":"Gaule","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib60","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/j.jtho.2016.09.006","article-title":"ORAL01.01: a prospective, multi-institutional assessment of four assays for PD-L1 expression in NSCLC by immunohistochemistry: topic: pathology","volume":"11","author":"Rimm","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib61","doi-asserted-by":"crossref","unstructured":"Ratcliffe MJ, Sharpe A, Midha A, et\u00a0al. Agreement between\u00a0programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancer [e-pub ahead of print]. Clin\u00a0Cancer Res. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-16-2375, accessed March 21, 2017.","DOI":"10.1158\/1078-0432.CCR-16-2375"},{"key":"10.1016\/j.jtho.2017.05.019_bib62","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jtho.2016.11.013","article-title":"Multicentric French harmonization study for PD-L1 IHC testing in NSCLC","volume":"12","author":"Adam","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2017.05.019_bib64","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT082","article-title":"Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026","volume":"77","author":"Peters","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.jtho.2017.05.019_bib65","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/JTO.0000000000000334","article-title":"The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer","volume":"9","author":"Rami-Porta","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib66","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Nicholson","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib67","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jtho.2016.06.028","article-title":"The IASLC Lung Cancer Staging Project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in\u00a0the forthcoming (eighth) edition of the TNM classification of lung cancer","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib68","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2016.03.025","article-title":"The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer","volume":"11","author":"Travis","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib69","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/JTO.0000000000000559","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"10","author":"Rami-Porta","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib70","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000678","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer","volume":"10","author":"Asamura","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib71","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib73","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jtho.2016.01.024","article-title":"The IASLC Lung Cancer Staging Project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib74","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2016.01.025","article-title":"The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtho.2015.12.114","article-title":"The IASLC Lung Cancer Staging Project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib76","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jtho.2015.12.113","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib77","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation","volume":"11","author":"Pass","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib78","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib79","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib80","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib81","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/JTO.0000000000000017","article-title":"The IASLC\/ITMIG Thymic Malignancies Staging Project: development of a stage classification for thymic malignancies","volume":"8","author":"Detterbeck","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib82","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/JTO.0000000000000303","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Nicholson","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib83","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1097\/JTO.0000000000000291","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Kondo","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib84","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1097\/JTO.0000000000000293","article-title":"The ITMIG\/IASLC Thymic Epithelial Tumors Staging Project: a proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors","volume":"9","author":"Bhora","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib85","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer","volume":"12","author":"Rice","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib87","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/dote.12493","article-title":"Worldwide Esophageal Cancer Collaboration: clinical staging data","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jtho.2017.05.019_bib88","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/dote.12520","article-title":"Worldwide Esophageal Cancer Collaboration: pathologic staging data","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jtho.2017.05.019_bib89","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/dote.12513","article-title":"Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jtho.2017.05.019_bib90","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dote.12538","article-title":"Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jtho.2017.05.019_bib91","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/dote.12533","article-title":"Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jtho.2017.05.019_bib92","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/dote.12540","article-title":"Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jtho.2017.05.019_bib93","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ejcts\/ezv154","article-title":"Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database","volume":"49","author":"Falcoz","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib94","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.athoracsur.2015.10.105","article-title":"Propensity score analysis comparing videothoracoscopic lobectomy with thoracotomy: a French nationwide study","volume":"101","author":"Pages","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib95","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jtho.2016.04.032","article-title":"Thoracoscopic lobectomy produces long-term survival similar to that with open lobectomy in cases of non-small cell lung carcinoma: a propensity-matched analysis using a population-based cancer registry","volume":"11","author":"Wang","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib96","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.athoracsur.2015.11.018","article-title":"Use and outcomes of minimally invasive lobectomy for stage I non-small cell lung cancer in the National Cancer Data Base","volume":"101","author":"Yang","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib97","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.athoracsur.2015.05.136","article-title":"Nodal upstaging during lung cancer resection is associated with surgical approach","volume":"101","author":"Martin","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib98","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtho.2015.10.007","article-title":"Nodal upstaging is more common with thoracotomy than with VATS During lobectomy for early-stage lung cancer: an analysis from the National Cancer Data Base","volume":"11","author":"Medbery","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib99","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(16)00173-X","article-title":"Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial","volume":"17","author":"Bendixen","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.athoracsur.2016.03.032","article-title":"Comparison of video-assisted thoracoscopic surgery and robotic approaches for clinical stage I and stage II non-small cell lung cancer using the Society of Thoracic Surgeons Database","volume":"102","author":"Louie","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2016.09.004","article-title":"Robot-assisted surgery for lung cancer: state of the art and perspectives","volume":"101","author":"Veronesi","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib102","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.athoracsur.2016.07.003","article-title":"Quality measures in clinical stage I non-small cell lung cancer: improved performance is associated with improved survival","volume":"103","author":"Samson","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib103","series-title":"American Association for Thoracic Surgery Annual Meeting","first-page":"18","article-title":"Surgical quality measures in stage IIIA non\u2013small cell lung cancer are associated with improved survival","author":"Samson","year":"2016"},{"key":"10.1016\/j.jtho.2017.05.019_bib104","first-page":"511","article-title":"The importance of lymph node dissection accompanying wedge resection for clinical stage IA lung cancer\u2020","volume":"51","author":"Stiles","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2017.05.019_bib105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/s10434-016-5509-4","article-title":"Rationale for a\u00a0minimum number of lymph nodes removed with non\u2013small cell lung cancer resection: correlating the number of nodes removed with survival in 98,970 patients","volume":"23","author":"Samayoa","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib106","doi-asserted-by":"crossref","first-page":"258","DOI":"10.21037\/tlcr.2016.06.13","article-title":"Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis","volume":"5","author":"Li","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib107","article-title":"Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER Database and a Chinese multi-institutional registry","author":"Liang","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib108","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12957-016-1048-5","article-title":"Lymph node ratio as a prognostic factor in\u00a0patients with pathological N2 non-small cell lung cancer","volume":"14","author":"Tamura","year":"2016","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib109","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2016.34.15_suppl.8507","article-title":"E1505: Adjuvant chemotherapy\u00a0+\/- bevacizumab for early stage NSCLC\u2014outcomes based on chemotherapy subsets","volume":"34","author":"Wakelee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib110","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.299","article-title":"Selection for adjuvant chemotherapy in stage IB non-small cell lung cancer: a propensity score-matched analysis","volume":"12","author":"Jeon","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib111","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/j.jtho.2016.11.278","article-title":"Randomized Controlled study comparing adjuvant versus neo-adjuvant chemotherapy in resectable stage IB to IIIA NSCLC","volume":"12","author":"Yang","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib112","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib113","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib115","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib116","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2016.34.15_suppl.8500","article-title":"Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer","volume":"34","author":"Liao","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib117","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib118","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib119","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000265","article-title":"Changes in treatment patterns and overall survival in patients with early-stage non-small cell lung cancer in the United States after the incorporation of stereotactic ablative radiation therapy: a population-based analysis","author":"Haque","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib120","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.cllc.2015.12.009","article-title":"Quality of life after stereotactic ablative radiotherapy for early-stage lung cancer: a systematic review","volume":"17","author":"Chen","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib121","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ijrobp.2016.06.035","article-title":"Efficacy and toxicity analysis of NRG Oncology\/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC)","volume":"96","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2017.05.019_bib122","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2015.09.028","article-title":"Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and long-term clinical outcomes","volume":"117","author":"Tekatli","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib123","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.jtho.2016.11.369","article-title":"The Nordic HILUS-Trial\u2014first report of a phase II trial of SBRT of centrally located lung tumors","volume":"12","author":"Lindberg","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib124","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/1097-0142(20010701)92:1<160::AID-CNCR1304>3.0.CO;2-X","article-title":"Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma","volume":"92","author":"Law","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib126","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib127","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib130","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/JCO.2016.34.15_suppl.9009","article-title":"Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Solomon","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib131","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2016.34.15_suppl.9007","article-title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): first report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA)","volume":"34","author":"Kim","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib132","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrclinonc.2012.43","article-title":"Treating ALK-positive lung cancer\u2014early successes and future challenges","volume":"9","author":"Camidge","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib133","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2017.05.019_bib134","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALKiInhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2017.05.019_bib135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib136","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-14-3009","article-title":"Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib","volume":"21","author":"Gainor","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib137","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cllc.2016.05.001","article-title":"Progression-free and overall survival of patients with ALK rearrangement-positive non-small cell lung cancer treated sequentially with crizotinib and alectinib","volume":"17","author":"Watanabe","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib138","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib139","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib140","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib141","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Pretreated T790M-positive advanced non\u2013small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J\u00a0Clinic Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib142","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib143","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib144","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2016.34.15_suppl.9002","article-title":"Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study","volume":"34","author":"Yang","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib145","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S1556-0864(16)30324-0","article-title":"Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts","volume":"11","author":"Ramalingam","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib146","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib147","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12929-016-0305-9","article-title":"Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors","volume":"23","author":"Liao","year":"2016","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.jtho.2017.05.019_bib148","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","article-title":"A\u00a0highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma","volume":"11","author":"Reckamp","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib149","doi-asserted-by":"crossref","first-page":"9044","DOI":"10.1200\/JCO.2016.34.15_suppl.9044","article-title":"Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M","volume":"34","author":"Tan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib150","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1200\/JCO.2016.34.15_suppl.9050","article-title":"Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: interim results from an ongoing phase 1 study","volume":"34","author":"Yu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib151","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1517\/14656566.2016.1162786","article-title":"Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions","volume":"17","author":"Chuang","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jtho.2017.05.019_bib152","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMc1602688","article-title":"Update to rociletinib data with the RECIST confirmed response rate","volume":"374","author":"Sequist","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib153","doi-asserted-by":"crossref","first-page":"368ra172","DOI":"10.1126\/scitranslmed.aag0976","article-title":"AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases","volume":"8","author":"Yang","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib154","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1200\/JCO.2016.34.15_suppl.9003","article-title":"Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM)","volume":"34","author":"Ahn","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib155","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib156","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib157","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib158","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib159","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-15-2013","article-title":"A\u00a0novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer","volume":"22","author":"Drilon","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib160","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib161","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-14-1350","article-title":"Molecular changes associated with acquired resistance to crizotinib in\u00a0ROS1-Rearranged non-small cell lung cancer","volume":"21","author":"Song","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib162","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1200\/JCO.2016.34.15_suppl.9072","article-title":"Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib","volume":"34","author":"Gainor","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib163","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/1078-0432.CCR-14-1385","article-title":"Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer","volume":"21","author":"Katayama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib164","doi-asserted-by":"crossref","first-page":"E5381","DOI":"10.1073\/pnas.1515281112","article-title":"Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors","volume":"112","author":"Davare","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2017.05.019_bib165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2017.05.019_bib166","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-2132","article-title":"The novel, rationally-designed, ALK\/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors","volume":"76","author":"Zhai","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib167","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jtho.2016.04.001","article-title":"An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer","volume":"11","author":"Dziadziuszko","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib168","doi-asserted-by":"crossref","first-page":"e82236","DOI":"10.1371\/journal.pone.0082236","article-title":"Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer","volume":"8","author":"Davies","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2017.05.019_bib169","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib170","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib171","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib172","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib173","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib174","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib175","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib176","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib177","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib178","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib179","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2016.34.15_suppl.108","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib180","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2014.32.15_suppl.8001","article-title":"Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)","volume":"32","author":"Camidge","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib181","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib182","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib183","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2016.34.15_suppl.9013","article-title":"A\u00a0phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement","volume":"34","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib184","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw383.05","article-title":"Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung","volume":"27","author":"Velcheti","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib185","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1200\/JCO.2016.34.15_suppl.9069","article-title":"Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion","volume":"34","author":"Cascone","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib186","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib187","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib188","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu438.47","article-title":"LBA39_PR. Neratinib (N) with or without temsirolimus (Tem) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib189","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib190","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/JTO.0000000000000644","article-title":"BRAF alterations as therapeutic targets in non-small-cell lung cancer","volume":"10","author":"Nguyen-Ngoc","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib191","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib192","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2015.62.0674","article-title":"Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations","volume":"34","author":"Liu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib193","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2017.05.019_bib194","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2017.05.019_bib195","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib196","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2015.10.028","article-title":"Responses to the multitargeted MET\/ALK\/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation","volume":"90","author":"Jorge","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib197","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2015-0510","article-title":"MET exon 14 skipping in non-small cell lung cancer","volume":"21","author":"Heist","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2017.05.019_bib198","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","article-title":"Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping","volume":"11","author":"Heist","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib199","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.2016.70.4064","article-title":"Karnofsky Award 2016: a lung cancer journey, 1973 to 2016","volume":"35","author":"Bunn","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","article-title":"Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches","volume":"10","author":"Shea","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jtho.2017.05.019_bib201","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2213-2600(16)30369-1","article-title":"Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?","volume":"5","author":"Drilon","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib202","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2016.34.15_suppl.9014","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from a global registry","volume":"34","author":"Gautschi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib203","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jtho.2016.02.016","article-title":"Pulse afatinib for ERBB2 exon 20 insertion-mutated lung adenocarcinomas","volume":"11","author":"Costa","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazieres","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib205","doi-asserted-by":"crossref","first-page":"e00023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2017.05.019_bib206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtho.2015.08.003","article-title":"FGFR signaling as a target for lung cancer therapy","volume":"11","author":"Desai","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib207","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib208","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14694\/EdBook_AM.2014.34.71","article-title":"National Cancer Institute's precision medicine initiatives for the new National Clinical Trials Network","author":"Abrams","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2017.05.019_bib209","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib210","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib211","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jtho.2016.11.010","article-title":"Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS \u226550%: data from KEYNOTE-024","volume":"12","author":"Brahmer","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib212","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.39","article-title":"NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV\/recurrent programmed death ligand 1 (PD-L1)\u2212positive NSCLC","volume":"27","author":"Socinski","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib213","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/j.jtho.2016.11.240","article-title":"JAVELIN solid tumor: safety and clinical activity of avelumab (anti-PD-L1) as first-line treatment in patients with advanced NSCLC","volume":"12","author":"Jerusalem","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib214","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib215","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.43","article-title":"Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L\/3L NSCLC","volume":"27","author":"Barlesi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib216","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib217","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1200\/jco.2014.32.15_suppl.8022","article-title":"Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC","volume":"32","author":"Rizvi","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib218","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1556-0864(16)30246-5","article-title":"Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib219","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib220","doi-asserted-by":"crossref","first-page":"e1094598","DOI":"10.1080\/2162402X.2015.1094598","article-title":"Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1\/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients","volume":"5","author":"Hong","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2017.05.019_bib221","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1200\/JCO.2016.34.15_suppl.9026","article-title":"Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro)","volume":"34","author":"Hui","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib222","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib223","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.2015.63.0970","article-title":"Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer","volume":"34","author":"Brambilla","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib224","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?","volume":"4","author":"Grigg","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2017.05.019_bib225","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer Immunology. The \u201ccancer immunogram\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2017.05.019_bib226","first-page":"76","article-title":"(Neo-)adjuvant ipilimumab\u00a0+ nivolumab (IPI\u00a0+ NIVO) in palpable stage 3 melanoma\u2014the OpACIN trial. Society for Melanoma Research 2016 Congress [abstract]","volume":"30","author":"Blank","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jtho.2017.05.019_bib227","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.38","article-title":"NSCLC, early stage neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer","volume":"27","author":"Forde","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib228","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib229","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ijrobp.2012.10.016","article-title":"Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey","volume":"85","author":"Komaki","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2017.05.019_bib230","doi-asserted-by":"crossref","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [e-pub ahead of print]. Lancet Oncol, accessed July 8, 2017.","DOI":"10.1016\/S1470-2045(17)30318-2"},{"key":"10.1016\/j.jtho.2017.05.019_bib231","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib232","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0167-8140(16)31389-5","article-title":"OC-0140: management of patients with extensive-stage small-cell lung cancer: a European survey of practice","volume":"119","author":"Haslett","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib233","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.ijrobp.2016.06.371","article-title":"Identifying patients with extensive-stage small cell lung cancer (ES-SCLC) most likely to benefit from intensive radiation therapy","volume":"96","author":"Slotman","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2017.05.019_bib234","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jtho.2016.01.012","article-title":"Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?","volume":"11","author":"Bunn","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrclinonc.2016.203","article-title":"Small-cell lung cancer in 2016: shining light on novel targets and therapies","volume":"14","author":"Rudin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib236","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib237","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/j.jtho.2016.11.250","article-title":"Pembrolizumab in patients with extensive-stage small cell lung cancer: updated survival results from KEYNOTE-028","volume":"12","author":"Ott","year":"2017","journal-title":"J\u00a0Thor Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib238","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A\u00a0DLL3-targeted antibody-drug conjugate eradicates\u00a0high-grade pulmonary neuroendocrine tumor-initiating cells in\u00a0vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2017.05.019_bib239","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib240","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jtho.2016.11.302","article-title":"Long-term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028","volume":"12","author":"Alley","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib241","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.jtho.2016.11.301","article-title":"Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis","volume":"12","author":"Kindler","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib242","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A\u00a0phase II study of nivolumab in malignant pleural mesothelioma (nivomes): with translational research (TR) biopies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib243","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib244","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2016.34.15_suppl.8502","article-title":"Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study","volume":"34","author":"Kindler","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib245","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/JCO.2016.34.15_suppl.8519","article-title":"Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy","volume":"34","author":"Zauderer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib246","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.019_bib247","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A\u00a0standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib248","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib249","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib250","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/JTO.0000000000000474","article-title":"Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer","volume":"10","author":"Romanus","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib251","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2013.53.1186","article-title":"Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer","volume":"32","author":"Djalalov","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib252","first-page":"630","article-title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","volume":"19","author":"Goeree","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jtho.2017.05.019_bib253","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jtho.2016.05.032","article-title":"A\u00a0cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC Including PD-L1 testing","volume":"11","author":"Matter-Walstra","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib254","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2016.07.028","article-title":"Checkpoint inhibitors in lung cancer are not immune from cost-effectiveness analysis","volume":"11","author":"Kelly","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.019_bib255","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417304276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417304276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:05:53Z","timestamp":1659060353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086417304276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":255,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1556086417304276"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2017.05.019","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scientific Advances in Thoracic Oncology 2016","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}